Cross-cultural treatment preferences: a call for diversity in drug development

Research output: Contribution to journalComment/DebateContributedpeer-review

Contributors

  • Dana M. Dijkgraaf - , Utrecht University (Author)
  • Pantea Kiani - , Utrecht University (Author)
  • Maureen N. Zijlstra - , Utrecht University (Author)
  • Joris C. Verster - , Utrecht University, Swinburne University of Technology, Department of Child and Adolescent Psychiatry and Psychotherapy (Author)

Abstract

Patient preferences for treatment characteristics—such as dosage form, taste, smell, and ingredients—play a key role in adherence, yet these preferences differ widely across cultures and are frequently overlooked in pharmaceutical development. Prescription medicines must meet strict safety and effectiveness standards, restricting flexibility, whereas over-the-counter supplements allow more freedom, though often without proven benefits. Developing diverse formulations is expensive and time-consuming, and patients need clear guidance to make informed choices without feeling overwhelmed or questioning their doctors. This tension highlights a disconnect between patient desires, scientific validation, and practical feasibility. We urge healthcare providers, pharmaceutical companies, and patients to engage in dialogue to discuss patient preferences and diversity in drug development. By creating treatments that reflect cultural needs and improving patient education, adherence and equity in healthcare can improve, provided the scientific, economic, and logistical hurdles are addressed effectively.

Details

Original languageEnglish
Pages (from-to)1047-1051
Number of pages5
JournalCurrent medical research and opinion
Volume41
Issue number6
Publication statusE-pub ahead of print - 23 Jul 2025
Peer-reviewedYes

Keywords

ASJC Scopus subject areas

Keywords

  • compliance, dosage form, Drug development, ingredients, patient preferences, treatment adherence